Table 3.
Molecular and phenotypic characteristics of CA-MRSA clones from hospital laboratories in the Andean Region.
| Country (No. isolates) | PFGE Pulsotype/Clone (%) | ST | SCCmecIV subtypea (%) | Virulence genes (% of isolates) | Resistance profileb (% of isolates) |
|---|---|---|---|---|---|
| Colombia (100) | ComA (98) | 8 | IVc-E (98) | bsaA (99) | TET (43), ERY (9), CLI (6), CIP (4), SXT (2), GEN (1) |
| IVa (1) | sek (93) | ||||
| IVNT (1) | seq (89) | ||||
| arcA (1) | |||||
| ComB (1) | 6 | IVb (100) | bsaA (100) | None | |
| ComC (1) | SLV of ST5 | IVa (100) | Negative | GEN (100), CHL (100) | |
| Ecuador (64) | ComA (100) | 8 | IVc-E (87) | bsaA (100) | TET (39), ERY (9), CIP (5), GEN (5), SXT (6), CHL (2) RIF (2) |
| IVa (11) | sek (98) | ||||
| IVNT (2) | seq (95) | ||||
| arcA (8) | |||||
| Venezuela (10) | ComA (50) | 8 | IVc-E (80) | bsaA (100) | TET (20), ERY (20), CLI (20), CIP (20) |
| IVa (20) | sek (80) | ||||
| seq(80) | |||||
| arcA (20) | |||||
| ComD (10) | 22 | IVa (100) | Negative | GEN (100) | |
| ComE (40) | 923 | IVa (100) | bsaA (100) | ERY (100), TET (100) | |
| sek (100) | |||||
| seq (100) |
a
SCCmecIV subtyping by multiplex PCR described by Milheirico et al.
b
Percentage of isolates resistant to ERY (erythromycin), CLI (clindamycin), CIP (ciprofloxacin), GEN (gentamicin), CHL (chloramphenicol), RIF (rifampin), TET (tetracycline), SXT (trimethoprim-sulfamethoxazole) and MIN (minocycline).
IVNT, Non-typeable SCCmec IV
SLV, single locus variant